$Zevra Therapeutics (ZVRA.US)$ Corporate Foundation
●
On Feb. 27, 2025, Zevra entered into an asset purchase agreement for the sale of a Rare Pediatric Disease Priority Review Voucher (PRV), issued by the U.S. FDA upon the approval of MIPLYFFA, for $150 million.

FY 2024 Financial Highlights
●
Revenue, Net: $23.6 million, comprised of $10.1 million in MIPLYFFA net revenue, $0.1 million in OLPRUVA net revenue, $9.1 million in in net reimbursements from the French expanded access program (...

$Zevra Therapeutics (ZVRA.US)$
How Will Zevra Use Its Massive $150M Windfall? Non-Dilutive Funding Fuels Rare Disease Strategy

$Zevra Therapeutics (ZVRA.US)$ Reuters· 1 min ago
Zevra Therapeutics Enters Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher for $150 Million

$Zevra Therapeutics (ZVRA.US)$ Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA (Arimoclomol) for Treatment of Niemann-Pick Disease Type C
GlobeNewswire· 7 mins ago
MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra's specialty pharmacy for dispense
AmplifyAssist, Zevra's comprehensive patient support program, in place to address access barriers

$Zevra Therapeutics (ZVRA.US)$
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics (ZVRA) announces the commercial availability of MIPLYFFA™ (arimoclomol), the first FDA-approved treatment for Niemann-Pick disease type C (NPC). The medication is indicated for use with miglustat to treat neurological manifestations in patients 2 years and older. The company reports early adoption exceeding expectat...

$Zevra Therapeutics (ZVRA.US)$
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting
Zevra Therapeutics (NASDAQ: ZVRA) announced the presentation of data validating the swallow domain's significance in the Niemann-Pick Disease Type C Clinical Severity Scale(NPCCSS) at the 53rd Child Neurology Society Annual Meeting. The study, presented by Dr. Elizabeth Berry-Kravis, in...

🚨 This Week’s PDUFAs:
$Heron Therapeutics (HRTX.US)$ : 🤔
⇨ ZYNRELEF® Vial Access Needle
‣ Postoperative pain
‣ PDUFA: 9/23/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ KarXT (xanomeline-trospium)
‣ Schizophrenia
‣ PDUFA: 9/26/24 (NDA)
$Sanofi (SNY.US)$ $Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Dupixent
‣ Chronic obstructive pulmonary disease
‣ PDUFA: 9/27/24 (sBLA)
$BeiGene (BGNE.US)$ $Merck & Co (MRK.US)$ & $Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Tislelizumab, KEYTRUDA, OPDIVO & YER...

$Zevra Therapeutics (ZVRA.US)$
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024
Zevra Therapeutics (NASDAQ: ZVRA) announced that top-line data from its Phase 2 clinical trial of KP1077 for idiopathic hypersomnia (IH) will be presented at Sleep Europe 2024. The trial (NCT05668754) was a placebo-controlled, double-blind, randomized withdrawal study evaluating the safety and tolerability of KP1077 (serdexmethylp...

$Zevra Therapeutics (ZVRA.US)$ wow no love for fda?